The Research Report on Cancer Diagnostics Market Consist 89 market data tables and 37 figures spread through 197 pages and in-depth TOC, which covers Global Market overview, Major Key Players detailed Analysis, market opportunities, market risk, forecast for the next five years, major driving factors for the market as well as detailed analysis for CAGR, scope, research findings, leading key players marketing strategy to acquire major market in the form of revenue.
Technological advancements in various fields such as biomarkers, imaging, biopsy, endoscopy; growing number of cancer cases, the rapid rise in geriatric population, awareness initiatives by governments, and increasing government funding are major factors driving the market growth.
The platform-based technology is further segmented into next-generation sequencing, microarrays, PCR, flow cytometry, in situ hybridization, immunohistochemistry, and others. Instrument-based cancer diagnostics is further segmented into imaging systems and biopsy.
Cancer Diagnostics Market, by Application
Cancer Diagnostics Market, by Product
Request Research Sample Pages:https://www.marketsandmarkets.com/requestsampleNew.asp?id=186559121
Based on region, the market is divided into North America, Europe, Asia, and Rest of the World (RoW). Rest of the World comprises Latin America, Pacific countries, and Middle East and Africa. North America is expected to account for the largest share in the cancer diagnostics market, followed by Europe and Asia. However, the Asian market is slated to grow at the highest CAGR in the coming five years and serves as a revenue pocket for the companies operating in the cancer diagnostics market.
Some of the major players in the global cancer diagnostics market include Agilent Technologies, Inc. (U.S.), Thermo Fisher Scientific, Inc. (U.S.), Illumina, Inc. (Denmark), Becton, Dickinson and Company (U.S.), GE Healthcare (U.K.), QIAGEN N.V. (Netherlands), Abbott Laboratories, Inc. (U.S.), Roche Diagnostics (Switzerland), Siemens Healthcare (Germany), Philips Healthcare (U.K.), and C.R. Bard, Inc. (U.S.).
We just sent you an email. Please click the link in the email to confirm your subscription!
OKSubscriptions powered by Strikingly